Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 adrenergic receptor antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alpha 1 adrenergic receptor antagonist: Overview
Alpha-1–adrenergic receptors (ARs) are G protein–coupled receptors activated by catecholamines. The alpha-1A and alpha-1B subtypes are expressed in mouse and human myocardium, whereas the alpha-1D protein is found only in coronary arteries. The alpha-1 adrenergic receptors activate the Gq/11 family of G proteins leading to the dissociation of the ? and ?? subunits and the subsequent stimulation of the enzyme phospholipase C. This enzyme hydrolyzes phosphatidylinositol 1,2-biphosphate in the membrane producing inositol trisphosphate (IP3) and diacylglycerol. These molecules act as second messengers mediating intracellular Ca2+ release via the IP3 receptor and activating protein kinase C. Alpha-1-adrenoreceptor antagonist drugs have the immediate attraction that there are no patient co-morbidities that constitute absolute contraindications to their use. Thus, alpha blockers can safely and appropriately be administered to hypertensive patients with concomitant disease states such as diabetes mellitus or obstructive airway disease or renal impairment.
Report Highlights
This segment of the Alpha 1 adrenergic receptor antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha 1 adrenergic receptor antagonist Emerging Drugs
Further product details are provided in the report……..
Alpha 1 adrenergic receptor antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Alpha 1 adrenergic receptor antagonist drugs segregated based on following parameters that define the scope of the report, such as:
Alpha 1 adrenergic receptor antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Alpha 1 adrenergic receptor antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha 1 adrenergic receptor antagonist drugs.
Alpha 1 adrenergic receptor antagonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 adrenergic receptor antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alpha 1 adrenergic receptor antagonist: Overview
Alpha-1–adrenergic receptors (ARs) are G protein–coupled receptors activated by catecholamines. The alpha-1A and alpha-1B subtypes are expressed in mouse and human myocardium, whereas the alpha-1D protein is found only in coronary arteries. The alpha-1 adrenergic receptors activate the Gq/11 family of G proteins leading to the dissociation of the ? and ?? subunits and the subsequent stimulation of the enzyme phospholipase C. This enzyme hydrolyzes phosphatidylinositol 1,2-biphosphate in the membrane producing inositol trisphosphate (IP3) and diacylglycerol. These molecules act as second messengers mediating intracellular Ca2+ release via the IP3 receptor and activating protein kinase C. Alpha-1-adrenoreceptor antagonist drugs have the immediate attraction that there are no patient co-morbidities that constitute absolute contraindications to their use. Thus, alpha blockers can safely and appropriately be administered to hypertensive patients with concomitant disease states such as diabetes mellitus or obstructive airway disease or renal impairment.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alpha 1 adrenergic receptor antagonist R&D. The therapies under development are focused on novel approaches for Alpha 1 adrenergic receptor antagonist.
This segment of the Alpha 1 adrenergic receptor antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha 1 adrenergic receptor antagonist Emerging Drugs
- TNX-102 SL: Tonix Pharmaceuticals
- Roluperidone: Minerva Neurosciences
Further product details are provided in the report……..
Alpha 1 adrenergic receptor antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Alpha 1 adrenergic receptor antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Alpha 1 adrenergic receptor antagonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Alpha 1 adrenergic receptor antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Alpha 1 adrenergic receptor antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha 1 adrenergic receptor antagonist drugs.
Alpha 1 adrenergic receptor antagonist Report Insights
- Alpha 1 adrenergic receptor antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Alpha 1 adrenergic receptor antagonist drugs?
- How many Alpha 1 adrenergic receptor antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha 1 adrenergic receptor antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha 1 adrenergic receptor antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha 1 adrenergic receptor antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tonix Pharmaceuticals
- Minerva Neurosciences
- INNOPHARMAX
- Bristol-Myers Squibb
- Kissei Pharmaceutical
- Pharmazz
- Ocularis Pharma
- Kinnov Therapeutics
- Ache Laboratories
- Ildong Pharmaceutical
- GL PharmTech
- Jeil Pharmaceutical
- Chong Kun Dang
- Ocuphire Pharma
- Fabre-Kramer Pharmaceuticals
- TNX-102 SL
- Roluperidone (MIN-101)
- C 08001
- Aripiprazole
- FKF 02SC
- Silodosin
- Centhaquine
- Phentolamine
- KT 110
- Phentolamine/pilocarpine
- ACH 000029
- Tadalafil/tamsulosin
- GL2701 CKD-825
- JLP-1207
Introduction
Executive Summary
Alpha 1 adrenergic receptor antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha 1 adrenergic receptor antagonist – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
FKF 02SC: Fabre-Kramer Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Centhaquine: Pharmazz
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ACH 000029: Ache Laboratories
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha 1 adrenergic receptor antagonist Key Companies
Alpha 1 adrenergic receptor antagonist Key Products
Alpha 1 adrenergic receptor antagonist- Unmet Needs
Alpha 1 adrenergic receptor antagonist- Market Drivers and Barriers
Alpha 1 adrenergic receptor antagonist- Future Perspectives and Conclusion
Alpha 1 adrenergic receptor antagonist Analyst Views
Alpha 1 adrenergic receptor antagonist Key Companies
Appendix
Executive Summary
Alpha 1 adrenergic receptor antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha 1 adrenergic receptor antagonist – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
FKF 02SC: Fabre-Kramer Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Centhaquine: Pharmazz
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ACH 000029: Ache Laboratories
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha 1 adrenergic receptor antagonist Key Companies
Alpha 1 adrenergic receptor antagonist Key Products
Alpha 1 adrenergic receptor antagonist- Unmet Needs
Alpha 1 adrenergic receptor antagonist- Market Drivers and Barriers
Alpha 1 adrenergic receptor antagonist- Future Perspectives and Conclusion
Alpha 1 adrenergic receptor antagonist Analyst Views
Alpha 1 adrenergic receptor antagonist Key Companies
Appendix